Imgatuzumab
Imgatuzumab
Imgatuzumab (pronunciation: im-ga-tu-zu-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a type of biological therapy that targets specific proteins on cancer cells to inhibit their growth and spread.
Etymology
The name "Imgatuzumab" follows the World Health Organization's guidelines for the nomenclature of monoclonal antibodies. The suffix "-mab" indicates that it is a monoclonal antibody, while the infix "-tuzu-" suggests that it is a humanized antibody.
Mechanism of Action
Imgatuzumab works by binding to the epidermal growth factor receptor (EGFR), a protein found on the surface of some cancer cells. By blocking EGFR, Imgatuzumab can inhibit the growth and division of cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Epidermal growth factor receptor (EGFR): A protein found on the surface of some cells to which epidermal growth factor binds, causing the cells to divide.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight cancer, infections, and other diseases.
See Also
External links
- Medical encyclopedia article on Imgatuzumab
- Wikipedia's article - Imgatuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski